The company has created a proprietary 3D genomic biomarker platform called EpiSwitch, which is used to build molecular diagnostic classifiers for predicting therapy response, patient prognosis, disease diagnosis, and monitoring residual disease. They have partnered with over 40 big pharma companies and leading institutions, and have a valuable technology portfolio including biomarker arrays, molecular diagnostic tests, and bioinformatic tools. Oxford BioDynamics is headquartered in Oxford, UK, listed on AIM of the London Stock Exchange, and has a commercial team in the US and a reference laboratory in Penang, Malaysia.